ACE: A BIOMARKER-BASED APPROACH TO IMPROVING ASTHMA CONTROL

ACE:基于生物标志物的改善哮喘控制的方法

基本信息

  • 批准号:
    7603396
  • 负责人:
  • 金额:
    $ 0.84万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-04-01 至 2007-09-16
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The prevalence of asthma has increased in many parts of the world. Evidence exists that children living in the inner cities of the United States, and living under economic disadvantages, constitute a unique and special at-risk population for asthma, which is characterized by increased morbidity and morality (Akinbami et al, 2002; Cloutier et al, 2002). The objectives of the National Institutes of Allergy and Infectious Diseases Inner City Asthma Consortium (ICAC) are (1) to identify forms of immune-based therapy that are likely to promote control and prevention of asthma, (2) to design protocols that will evaluate immune-based therapies in the treatment of asthma in low-income inner-city adolescents, and (3) to determine both the mechanisms of immune-based therapies and the potential unique mechanisms associated with the pathogenesis of asthma in low-income inner-city adolescents by the conduct of parallel mechanistic investigations with the therapeutic protocols. The availability of biomarkers in the clinical management of asthma presents presents an opportunity to apply this measurement to a specific subpopulation of patients who remain refractory to the conventional approach to asthma management. The population of urban, inner-city adolescents with asthma is a particularly susceptible group who are subject to a severe degree of morbidity. The potential application of biomarker measurement in the form of exhaled nitric oxide presents an opportunity to manage and control asthma as an adjunct to NAEPP guidelines. The ICAC therefore has conducted a randomized, prospective, double-blind parallel group trial involving inner city adolescents, ages 12-20 years, with persistent asthma.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gordon R. Bloomberg其他文献

Oral challenge outcomes in children with adverse aminopenicillin reactivity
  • DOI:
    10.1016/j.anai.2019.01.008
  • 发表时间:
    2019-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Alysa G. Ellis;Gordon R. Bloomberg
  • 通讯作者:
    Gordon R. Bloomberg

Gordon R. Bloomberg的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gordon R. Bloomberg', 18)}}的其他基金

INNER CITY ASTHMA CONSORTIUM: URBAN ENVIRONMENT AND CHILDHOOD ASTHMA
内城哮喘协会:城市环境与儿童哮喘
  • 批准号:
    7603394
  • 财政年份:
    2007
  • 资助金额:
    $ 0.84万
  • 项目类别:
INNER CITY ASTHMA CONSORTIUM: URBAN ENVIRONMENT AND CHILDHOOD ASTHMA
内城哮喘协会:城市环境与儿童哮喘
  • 批准号:
    7377265
  • 财政年份:
    2006
  • 资助金额:
    $ 0.84万
  • 项目类别:
ACE: A BIOMARKER-BASED APPROACH TO IMPROVING ASTHMA CONTROL
ACE:基于生物标志物的改善哮喘控制的方法
  • 批准号:
    7377267
  • 财政年份:
    2006
  • 资助金额:
    $ 0.84万
  • 项目类别:
ACE: A BIOMARKER-BASED APPROACH TO IMPROVING ASTHMA CONTROL
ACE:基于生物标志物的改善哮喘控制的方法
  • 批准号:
    7198772
  • 财政年份:
    2005
  • 资助金额:
    $ 0.84万
  • 项目类别:

相似国自然基金

靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0 万元
  • 项目类别:
    面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
  • 批准号:
    2023JJ50274
  • 批准年份:
    2023
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    33 万元
  • 项目类别:
    地区科学基金项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
  • 批准号:
    n/a
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
  • 批准号:
    81973577
  • 批准年份:
    2019
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
  • 批准号:
    81602908
  • 批准年份:
    2016
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
  • 批准号:
    81501928
  • 批准年份:
    2015
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

The effect of e-cigarette and hookah use on the age of asthma onset in the USA
使用电子烟和水烟对美国哮喘发病年龄的影响
  • 批准号:
    10704075
  • 财政年份:
    2022
  • 资助金额:
    $ 0.84万
  • 项目类别:
Nasal microRNA during bronchiolitis and age 6y asthma phenotypes: MARC-35 cohort
细支气管炎和 6 岁哮喘表型期间的鼻 microRNA:MARC-35 队列
  • 批准号:
    10267407
  • 财政年份:
    2020
  • 资助金额:
    $ 0.84万
  • 项目类别:
Evaluating the risk of asthma at age 5 and 10 years in children diagnosed with bronchiolitis during infancy - a study merging emergency department-based clinical data from the Canadian Bronchiolitis Epinephrine Steroid Trial (CanBEST), and the Bronchiolit
评估婴儿期被诊断患有细支气管炎的儿童在 5 岁和 10 岁时患哮喘的风险 - 一项合并了加拿大细支气管炎肾上腺素类固醇试验 (CanBEST) 和 Bronchiolit 的急诊科临床数据的研究
  • 批准号:
    421854
  • 财政年份:
    2019
  • 资助金额:
    $ 0.84万
  • 项目类别:
    Operating Grants
Investigating the developmental origins of childhood asthma and allergies: Maternal prenatal social stress, infant immune cell epigenetic patterns, and risk for early childhood asthma and allergies at 3- and 5-years of age
调查儿童哮喘和过敏的发育起源:母亲产前社会压力、婴儿免疫细胞表观遗传模式以及 3 岁和 5 岁时儿童早期哮喘和过敏的风险
  • 批准号:
    397252
  • 财政年份:
    2018
  • 资助金额:
    $ 0.84万
  • 项目类别:
    Fellowship Programs
Maternal carriage of Prevotella during pregnancy influences offspring innate immune responses and asthma at age 7
怀孕期间母亲携带普雷沃氏菌会影响后代 7 岁时的先天免疫反应和哮喘
  • 批准号:
    nhmrc : GNT1147980
  • 财政年份:
    2018
  • 资助金额:
    $ 0.84万
  • 项目类别:
    Project Grants
Maternal carriage of Prevotella during pregnancy influences offspring innate immune responses and asthma at age 7
怀孕期间母亲携带普雷沃氏菌会影响后代 7 岁时的先天免疫反应和哮喘
  • 批准号:
    nhmrc : 1147980
  • 财政年份:
    2018
  • 资助金额:
    $ 0.84万
  • 项目类别:
    Project Grants
SOLAR III: Asthma and allergies from school age up to working life - analyses of occupational exposures and transgenerational effects over three generations.20-years Follow-up of the ISAAC Phase II Study in Germany.
SOLAR III:从学龄到工作生活的哮喘和过敏 - 对三代人的职业暴露和跨代影响的分析。德国 ISAAC 第二阶段研究的 20 年随访。
  • 批准号:
    314488639
  • 财政年份:
    2016
  • 资助金额:
    $ 0.84万
  • 项目类别:
    Research Grants
Age-Dependent Pharmacogenomics of Asthma Treatment (ADAPT)
哮喘治疗的年龄依赖性药物基因组学 (ADAPT)
  • 批准号:
    9229561
  • 财政年份:
    2016
  • 资助金额:
    $ 0.84万
  • 项目类别:
Nasal microRNA during bronchiolitis and age 6y asthma phenotypes: MARC-35 cohort
细支气管炎和 6 岁哮喘表型期间的鼻 microRNA:MARC-35 队列
  • 批准号:
    9215155
  • 财政年份:
    2016
  • 资助金额:
    $ 0.84万
  • 项目类别:
Airway microbiome and age 6y asthma phenotypes in 2 diverse multicenter cohorts
2 个不同多中心队列中的气道微生物组和 6 岁哮喘表型
  • 批准号:
    10242707
  • 财政年份:
    2016
  • 资助金额:
    $ 0.84万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了